Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $2.3 million.

  • Northwest Biotherapeutics' Prepaid Assets rose 3.28% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 3.28%. This contributed to the annual value of $1.9 million for FY2024, which is 5.60% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Prepaid Assets is $2.3 million, which was up 26.54% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Prepaid Assets peaked at $5.7 million during Q1 2021, and registered a low of $1.7 million during Q3 2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Prepaid Assets value was $2.1 million (recorded in 2024), while the average stood at $2.3 million.
  • Data for Northwest Biotherapeutics' Prepaid Assets shows a peak YoY increase of 102.96% (in 2021) and a maximum YoY decrease of 61.63% (in 2021) over the last 5 years.
  • Northwest Biotherapeutics' Prepaid Assets (Quarterly) stood at $2.1 million in 2021, then rose by 15.98% to $2.5 million in 2022, then decreased by 18.74% to $2.0 million in 2023, then declined by 5.60% to $1.9 million in 2024, then rose by 3.28% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.